Matchpoint Gets $100M to Take Covalent Binders Into Autoimmune Disease

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Atlas, Medicxi Invest $70M in Antibody for Obesity Licensed from Novartis
The Vintage of 2020: How COVID-19 is Molding Biotech Startups
Atlas Venture Closes Fund XII at $400 Million, Promotes Gladstone to Partner
Matching Up Technology & People: Bruce Booth on The Long Run Podcast